Takeda Pharmaceutical Company Limited and Arbor Pharmaceuticals Ireland Ltd., a wholly-owned subsidiary of Arbor Pharmaceuticals, LLC announced that Takeda and...
Results of a 12-week, head-to-head, Phase III study found systolic blood pressure (SBP) reductions of Edarbyclor (azilsartan medoxomil and chlorthalidone),...
Results of a 10-week, Phase III study of Edarbyclor (azilsartan medoxomil and chlorthalidone), from Takeda, for patients with Hypertension found...